WO2017147820A1 - Vecteur de médicament à double ciblage - Google Patents
Vecteur de médicament à double ciblage Download PDFInfo
- Publication number
- WO2017147820A1 WO2017147820A1 PCT/CN2016/075329 CN2016075329W WO2017147820A1 WO 2017147820 A1 WO2017147820 A1 WO 2017147820A1 CN 2016075329 W CN2016075329 W CN 2016075329W WO 2017147820 A1 WO2017147820 A1 WO 2017147820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- target
- vegf
- rgd
- egf
- dual
- Prior art date
Links
- 239000003937 drug carrier Substances 0.000 title claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 235000018102 proteins Nutrition 0.000 claims description 28
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 24
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 24
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 23
- 230000009977 dual effect Effects 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 15
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 15
- 230000002285 radioactive effect Effects 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims description 7
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 229940009098 aspartate Drugs 0.000 claims description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 4
- 108010051479 Bombesin Proteins 0.000 claims description 3
- 102000013585 Bombesin Human genes 0.000 claims description 3
- 102400000921 Gastrin Human genes 0.000 claims description 3
- 108010052343 Gastrins Proteins 0.000 claims description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 3
- 108010016076 Octreotide Proteins 0.000 claims description 3
- 108010073235 asparagine-glycine-arginine Proteins 0.000 claims description 3
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 3
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 229960003330 pentetic acid Drugs 0.000 claims description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 229960002700 octreotide Drugs 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 2
- 230000008685 targeting Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 2
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 57
- 102000037865 fusion proteins Human genes 0.000 description 31
- 108020001507 fusion proteins Proteins 0.000 description 31
- 230000027455 binding Effects 0.000 description 22
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 20
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 15
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 15
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 15
- 101800003838 Epidermal growth factor Proteins 0.000 description 12
- 102400001368 Epidermal growth factor Human genes 0.000 description 12
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 229940116977 epidermal growth factor Drugs 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000010494 dissociation reaction Methods 0.000 description 10
- 230000005593 dissociations Effects 0.000 description 10
- 108091008605 VEGF receptors Proteins 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 8
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 229910001425 magnesium ion Inorganic materials 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000002603 single-photon emission computed tomography Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- -1 RGD-VEGF Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
- RXACEEPNTRHYBQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-sulfanylacetyl)amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CS RXACEEPNTRHYBQ-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BPNZYADGDZPRTK-UDUYQYQQSA-N Exametazime Chemical compound O/N=C(\C)[C@@H](C)NCC(C)(C)CN[C@H](C)C(\C)=N\O BPNZYADGDZPRTK-UDUYQYQQSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 229910021617 Indium monochloride Inorganic materials 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000010968 computed tomography angiography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 108010059304 cyclo(aspargyl-glycyl-arginyl) Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960000221 exametazime Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- APHGZSBLRQFRCA-UHFFFAOYSA-M indium(1+);chloride Chemical compound [In]Cl APHGZSBLRQFRCA-UHFFFAOYSA-M 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229950009151 mertiatide Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- HJZKOAYDRQLPME-UHFFFAOYSA-N oxidronic acid Chemical compound OP(=O)(O)C(O)P(O)(O)=O HJZKOAYDRQLPME-UHFFFAOYSA-N 0.000 description 1
- 229960004230 oxidronic acid Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004113 tetrofosmin Drugs 0.000 description 1
- QCWJONLQSHEGEJ-UHFFFAOYSA-N tetrofosmin Chemical compound CCOCCP(CCOCC)CCP(CCOCC)CCOCC QCWJONLQSHEGEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Definitions
- the present invention relates to a novel target drug carrier, and in particular to a dual target drug carrier having two target molecules.
- Cancer is the leading cause of death in the United States, and cancer mortality continues to increase. Cancer is the inability of cells to divide, grow and differentiate normally. The initial clinical manifestations of cancer are extremely uneven, with almost 70 cancers occurring in human organs and tissues, and some of these similar cancer types belong to many different molecular diseases. Unfortunately, some cancers may have no actual symptoms until late in the course of the disease, making treatment and prognosis extremely difficult.
- Cancer treatment usually includes surgery, chemotherapy, and/or radiation therapy. All current therapies have serious side effects and reduce the quality of life. Most chemotherapeutic drugs act on both normal and cancerous tissues. Therefore, one of the challenges in treating cancerous tumors is to give cancer cells maximum killing while minimizing damage to healthy tissue. Depending on the drug (eg, intravenous) and nature of the route of administration (eg, its physical and pharmacokinetic properties), typically only a small fraction of the administered dose reaches the target cell, with the remainder acting on other tissues or rapidly disappearing.
- drug eg, intravenous
- nature of the route of administration eg, its physical and pharmacokinetic properties
- Tumor neovascular endothelial cells express a large number of specific membrane proteins, including ⁇ v ⁇ 3, ⁇ v ⁇ 5, integrin, and vascular-related growth factors.
- RGD short-chain peptides
- tumor cells are highly unstable and variability, and are resistant to drugs during treatment. At present, various drugs and diagnostic agents are still slow and ineffective in improving the survival of cancer patients.
- the present invention provides a novel vector that can be used to diagnose and treat cancer.
- the dual target drug carrier of the invention is a fusion protein platform, which can effectively reduce the threshold and cost of the pharmaceutical technology.
- the invention provides a dual target drug carrier comprising a first target molecule and a second target molecule.
- the first or second target molecule specifically binds to vascular endothelial cells in tumor cells or/and tumor microenvironment
- the first and second target molecules include, but are not limited to, arginine-glycine-aspartate (RGD), asparagine-glycine-arginine (NGR) ), cyclic NGR (cyclic asparagine-glycine-arginine), internalization of RGD (iRGD, internalization-arginine-glycine-aspartate), cystine-glycine-aspartate Acid-lysine-arginine-threonine-arginine-glycine-alanine (CGNKRTRGA), stomach Gastrin, bombesin, octreotide or a derivative thereof.
- RGD arginine-glycine-aspartate
- NGR asparagine-glycine-arginine
- cyclic NGR cyclic asparagine-glycine-arginine
- internalization of RGD iRGD, internalization-arginine-glycine-aspartate
- Macromolecular peptides include, but are not limited to, epidermal growth factor (EGF), anti-EGFR (epidermal growth factor receptor) antibody, vascular endothelial growth factor (VEGF), anti-VEGFR ( Vascular Endothelial Growth Factor Receptor, anti-HER2 (human epidermal growth factor receptor 2) antibody, hepatocyte growth factor receptor (HGFR), anti-HIV - HGFR antibody, tumor necrosis factor (TNF) or anti-TNF antibody.
- EGF epidermal growth factor
- VEGF vascular endothelial growth factor
- anti-HER2 human epidermal growth factor receptor 2
- HGFR hepatocyte growth factor receptor
- TNF tumor necrosis factor
- the first target molecule is linked to the second target molecule by a linker.
- the connector is a peptide having 5 to 20 amino acids.
- the linker comprises, but is not limited to, GG, PGGGG or GGGGSGGGGS, wherein G represents glycine, P represents proline, and S represents serine.
- a radioisotope is further included.
- the invention further provides a pharmaceutical composition comprising the above dual target pharmaceutical carrier and a pharmaceutically acceptable carrier.
- a liposome is further included.
- nanoparticles are further included.
- Figure 1A shows purified VEGF, RGD-VEGF, RGD4C-VEGF, EGF, SDS-PAGE electropherogram of RGD-EGF and RGD4C-EGF protein.
- Figure 1B is a SDS-PAGE electrophoresis map of marker, VEGF, RGD-VEGF, and RGD4C-VEGF, wherein M is marker, 1 is VEGF (15.3 Da), 2 is RGD-VEGF (15.6 Da), and 3 is RGD4C-VEGF ( 16.3Da).
- FIGS. 2A-2F are binding curves/bar graphs of RGD-VEGF and RGD4C-VEGF and ⁇ v ⁇ 3, VEGFR1, VEGFR2.
- RGD-EGF and RGD4C-EGF bind to ⁇ v ⁇ 3 and EGFR, respectively.
- Figure 2A is a graph showing the binding of RGD-VEGF and RGD4C-VEGF to ⁇ v ⁇ 3.
- Figure 2B is a bar graph of competition of RGDfV polypeptide with RGD-VEGF and RGD4C-VEGF in combination with ⁇ v ⁇ 3.
- Figure 2C is a graph showing the binding of RGD-VEGF and RGD4C-VEGF to VEGFR1.
- Figure 2D is a graph showing the binding of RGD-VEGF and RGD4C-VEGF to VEGFR2.
- Figure 2E is a bar graph of competition of VEGFR2 antibodies by RGD-VEGF and RGD4C-VEGF in combination with VEGFR2.
- Figure 2F is a graph showing the binding of RGD-EGF and RGD4C-EGF to ⁇ v ⁇ 3.
- Figure 3A is a graph showing the binding of U87MG (expressing ⁇ v ⁇ 3 and EGFR) cells to RGD-VEGF and RGD4C-VEGF.
- RGD-VEGF and RGD4C-VEGF can bind to ⁇ v ⁇ 3 and EGFR, respectively.
- Figure 3B is a bar graph of binding of U87MG (expressing ⁇ v ⁇ 3 and EGFR) cells to RGD-VEGF and RGD4C-VEGF.
- Figure 3C is a graph showing the binding of HUVEC (expressing VEGFR1, VEGFR2 and ⁇ v ⁇ 3) cells to RGD-VEGF, RGD4C-VEGF and NGR-VEGF.
- RGD-VEGF, RGD4C-VEGF and NGR-VEGF can bind to express VEGFR1 Cells of VEGFR2 and ⁇ v ⁇ 3.
- Figure 3D is a bar graph of binding of HUVEC (expressing VEGFR1, VEGFR2 and ⁇ v ⁇ 3) cells to RGD-VEGF, RGD4C-VEGF and NGR-VEGF.
- Figures 4A-4D are cell adhesion assays. After coating RGD-VEGF and RGD4C-VEGF on the cell plate, the number of U87MG cells and HUVEC cells attached to the culture plate can be increased. If a large amount of RGD peptide chain is added to compete, the adsorption of cells can be reduced. 4A shows that RGD-VEGF and RGD4C-VEGF are applied to the cell plate to increase the number of U87MG cells attached to the culture plate, and FIG. 4B shows the amount of cells attached to the culture plate after the addition of the RGDfV polypeptide.
- Figure 4C-4D shows that RGD-VEGF and RGD4C-VEGF bind to HUVEC cells, and then compete with RGDfV polypeptide or VEGFR2 recombinant protein, respectively, in terms of absorbance and percentage.
- Figures 5A-5B show that RGD-EGF and RGD4C-EGF or RGD-VEGF and RGD4C-VEGF activate a signaling pathway downstream of EGFR or VEGFR, respectively.
- the EGF or VEGF of the dual target drug carrier of the invention retains its original biological properties.
- M of Figure 5A is Marker
- C is the control group (no protein added)
- E is EGF (25 nM)
- RE is RGD-EGF (25 nM)
- R4C-E is RGD4C-EGF (25 nM)
- C of Figure 5B For the control group (no protein added), RV is RGD-VEGF, R4-V RGD4C-VEGF.
- Figure 6 is a graph showing the stability of a radiolabeled fusion protein in a buffer solution (HEPES, 4 ° C) and serum (37 ° C).
- the radiolabeled fusion protein was stored in Hepes buffer (4 ° C) and fetal bovine serum (37 ° C), and the radiochemical purity was still higher than 90% after 24 hours, indicating the radioactive In-111-labeled fusion protein.
- the serum stability is excellent.
- Fig. 7 is a fluorescent photograph.
- the RGD-VEGF and RGD4C-VEGF marker recombinant proteins can bind to cells.
- Figure 8 is a single photon and computed tomography (SPECT/CT) angiogram of radiolabeled recombinant protein.
- U87MG subcutaneous tumor mice were injected with 111 In-DTPA (Diethylene triamine pentacetate aci)-EGF, 111 In-DTPA-RGD-EGF and 111 In-DTPA-RGD4C-EGF.
- Small animal single photon and computed tomography (SPECT/CT) angiography was performed at 4, 8 and 24 hours.
- SPECT/CT computed tomography
- the image shows that after the In-111 marker recombinant protein is applied, the specific accumulation of the tumor in the tumor (expressed as the tumor/muscle accumulation ratio) increases with time, reaching a peak at 8 hours after the drug injection, at this time 111 In
- the tumor/muscle accumulation ratio of -DTPA-RGD4C-EGF was 4.4, slightly higher than 3.6 of 111 In-DTPA-RGD-EGF, and much higher than 1.7 of 111 In-DTPA-EGF.
- the invention provides a dual target drug carrier comprising a first target molecule and a second target molecule.
- the target molecule of the present invention is a peptide, antibody or protein.
- the target molecules of the invention can be chemically modified to increase stability.
- Chemically modified peptides or peptide analogs include any chemically functional equivalent that increases stability and/or potency either in vivo or in vitro.
- a peptide analog refers to an amino acid derivative of any peptide.
- Peptide analogs include, but are not limited to, modified branches upon synthesis, combined with unsaturated amino acids and/or derivatives thereof, cross-linking and other methods that increase the peptide identity.
- a branched modification includes a modification of an amine group.
- the target molecule can bind to the lesion tissue in vivo and in vitro, especially for vascular endothelial cells of tumor, cancer tissue/cell and tumor microenvironment. Therefore, when the target peptide is conjugated to a reporter molecule (bioimaging fluorescent molecule or radiation), the tumor target peptide can directly display the tumor location and contribute to the diagnosis of cancer.
- Conjugation as used in the present invention means that two molecules that contribute to the treatment/diagnosis of a tumor, such as a tumor target peptide and a reporter molecule, are bound by sufficient affinity. Conjugation can be accomplished by covalent, non-covalent bonds or other forms of bonding, for example, coating.
- the target molecule of the present invention may be a small molecule peptide and/or a macropeptide.
- Small molecule peptides include, but are not limited to, lysine-glycine-aspartate (RGD), asparagine-glycine-arginine (NGR), cyclic NGR, internalization RGD (iRGD), cystine - glycine-aspartate-lysine-arginine-threonine-arginine-glycine-alanine (CGNKRTRGA), gastrin, bombesin, octreotide Octreotide) or a derivative thereof.
- RGD lysine-glycine-aspartate
- NGR asparagine-glycine-arginine
- iRGD internalization RGD
- gastrin bombe
- Macromolecular peptides include, but are not limited to, epidermal growth factor (EGF), anti-EGFR antibodies, vascular endothelial growth factor (VEGF), anti-VEGFR antibodies, anti-HER2 antibodies, hepatocyte growth factor receptor (HGFR), Anti-HGFR antibody, tumor necrosis factor (TNF) or anti-TNF antibody.
- EGF epidermal growth factor
- VEGF vascular endothelial growth factor
- HGFR hepatocyte growth factor receptor
- TNF tumor necrosis factor
- the target molecule can form a conjugate with an imaging substance or a radiotherapeutic substance (radiopharmaceutical or isotope).
- Radioactive imaging materials include, but are not limited to, 122 I, 123 I, 124 I, 125 I, 131 I, 18 F, 75 Br, 76 Br, 76 Br, 77 Br, 211 At, 225 Ac, 177 Lu, 153 Sm , 186 Re, 188 Re, 67 Cu, 213 Bi, 212 Bi, 212 Pb and 67 Ga.
- Radiopharmaceuticals include, but are not limited to, 111 In hydroxyquinoline, 131 I sodium iodide, 99m Tc phenyl bromide, 99m Tc red blood cells, 123 I sodium iodide, 99m Tc Exametazime, 99m Tc large particle polymeric albumin, 99m Tc-methylene phosphonate, 99m Tc Mertiatide, 99m Tc hydroxymethylene diphosphonate, 99m Tc triamine pentaacetic acid, 99m Tc Pertechnetate, 99m TcSestamibi, 99m Tc sulphur colloid, 99m Tc Tetrofosmin, 201 Tl and 133 Xe .
- Radiation isotopes include, but are not limited to, 52 Fe, 52 mMn, 55 Co, 64 Cu, 67 Ga, 68 Ga, 99 mTc, 111 In, 123 I, 125 I, 131 I, 32 P, 47 Sc, 67 Cu, 90 Y, 109 Pd, 111 Ag, 149 Pm, 186 Re, 188 Re, 211 At, 212 Bi, 213 Bi, 105 Rh, 153 Sm, 177 Lu and 198 Au.
- Non-gastrointestinal as used in the present invention includes subcutaneous, intradermal, intravenous, intramuscular, articular, arterial, synovial, focal or intracranial injections.
- the "linker” as used in the present invention refers to a sequence of 2 to 50 synthetic amino acids, preferably 5 to 20 synthetic amino acids, which are linked to two peptide sequences, for example, to link two peptide structures.
- the connector of the present invention can link two amino acid sequences through a peptide bond.
- the linker peptide of the present invention is a linear sequence linking the first portion to the second portion.
- the replaceable connector may be (GGGGS)n, (G)n, (EAAAK)n, (XP)n or (PAPAP)n, eg, GG, GGSG, GGGS, GGGGS, GGSGG, GGGSGG, GGGSGGG, GGGSGGGS, GGGSGGGGS, ASGG, GGGSASGG, SGCGS, GGGGSGGGG, GGSHG, SGCGGGS, and AACAA, wherein said G represents glycine; said S represents serine; said E represents glutamic acid; said A represents alanine; K represents lysine; P represents valine; said H represents histidine; and C represents cystine.
- the dual target drug carrier of the present invention can carry a tumor therapeutic drug or It is a substance (such as a therapeutic radionuclide) that becomes a tumor target drug carrier.
- a drug capable of molecular imaging can also be carried as a molecular imaging probe for tumor diagnosis.
- the double target developer carrier of the invention has the effect of tumor diagnosis.
- EGF, RGD-EGF, RGD4C-EGF, VEGF, RGD-VEGF and RGD4C-VEGF genes were constructed in the expression vector of pET28a(+) with Nco I and Xho I restriction enzyme cleavage sites.
- the C-terminus (ie, the carbon terminus) of RGD and RGD4C is ligated to the N-terminus (ie, the nitrogen terminus) of EGF or VEGF, and the C-terminus of EGF or VEGF has a His 6 flag.
- the His 6 marker facilitates subsequent purification and analysis, wherein the gene sequences of RGD-EGF, RGD4C-EGF, RGD-VEGF, and RGD4C-VEGF comprise the linker GG.
- the constructed pET28a(+) EGF, RGD-EGF, RGD4C-EGF, VEGF, RGD-VEGF and RGD4C-VEGF expression vectors were transfected into E. coli.DH5 ⁇ to produce and preserve vector DNA. The sequence was confirmed by DNA sequencing.
- Example 1 The vector of Example 1 was sent to E. coli BL21 (DE3) by heat shock, and screened and confirmed by kanamycin (50 ⁇ g/mL).
- the E. coli BL21 (DE3) strain carrying the protein expression vector was induced with 1 mM IPTG for 16 hours at 37 °C.
- the bacterial solution was sterilized by a French press at a pressure of 30 PSI, centrifuged at 13,000 g for 30 minutes, and samples of the supernatant and the pellet were collected for SDS-PAGE electrophoresis analysis, and observed by SDS-PAGE. Performance to the target fusion protein. If it is in the form of an insoluble body, the bacteria are present in the form of an insoluble body.
- Subsequent protein production receives a pellet after the disruption for protein purification.
- the lysed target fusion protein was filtered through a 0.45 ⁇ m filter, followed by a 1:50 ratio of refolding buffer (20 mM Tris, 0.1 Mm GSSG, 1 mM GSH, 1 mM EDTA pH 8.0). Dilution refolding.
- the target protein sample was slowly added to the refolding buffer, and the concentration of the target fusion protein after dilution was not more than 0.2 mg/ml, and the renaturation was carried out at 4 ° C for 12 hours, and then filtered through a 0.45 ⁇ m filter to remove the precipitate.
- Target protein was carried out at 4 ° C for 12 hours, and then filtered through a 0.45 ⁇ m filter to remove the precipitate.
- the protein refolding solution was passed through a nickel column at a flow rate of 5 mL/min.
- the column was first washed with buffer A (20 mM Tris (pH 8.0), 500 mM NaCl, 20 mM imidazole, 0.5 mM PMSF), followed by washing, using buffer A and buffer B (20 mM Tris (pH 8.0), The ratio of the imidazole of the solution was adjusted in proportion to 500 mM NaCl, 500 mM imidazole, 0.5 mM PMSF) to wash out the target fusion protein. Since the collected target fusion protein still has other impurity proteins, the fusion protein was isolated using a gel column (HiPrap 26/60S-100).
- EGF EGF
- RGD-EGF NGR-EGF
- RGD4C-EGF VEGF
- RGD-VEGF RGD-VEGF
- NGR-VEGF NGR-VEGF
- RGD4C-VEGF target fusion proteins target fusion proteins to cells was analyzed by ELISA cell binding assay.
- 25 ⁇ g/well of integrin ( ⁇ v ⁇ 3) receptor dissolved in PBS (calcium and magnesium ions) was placed in a 96well ELISA microplate, and cultured at 4 ° C for 12 hours, and then reacted with 3% BSA at 25 ° C for 1 hour.
- the serially diluted target fusion protein was added to culture at 25 ° C for 2 hours, and after washing with PBS buffer (containing calcium and magnesium ions), the mouse anti-His-HRP antibody was used to detect the binding of the protein to the receptor, and the wavelength was measured. The absorbance at 450 nm is used to quantify the amount of protein bound to the receptor.
- the obtained data using the prism software for nonlinear curve fitting can obtain the dissociation constant K d value of protein binding, which can be used as a comparison of the binding ability of the protein to different receptors.
- the mouse anti-His-HRP antibody was used to detect binding of the protein to the receptor, and the absorbance at a wavelength of 450 nm was measured to quantify the amount of protein bound to the receptor.
- the obtained data using the prism software for nonlinear curve fitting can obtain the dissociation constant Kd value of protein binding, which can be used as a comparison of the binding ability of the protein to different receptors.
- the dissociation constant K d values of EGF, RGD-EGF, RGD4C-EGF and EGFR were 2.38, 20.35 and 14.33 nM, respectively.
- the dissociation constant K d values of VEGF, RGD-VEGF, RGD4C-VEGF and Integrin were 0, 5.0 and 1.0, respectively.
- VEGF, RGD-VEGF, VEGFR1 solution RGD4C-VEGF with a dissociation constant K d values of 15.3,11.3 and 11.4.
- the dissociation constant K d values of VEGF, RGD-VEGF, RGD4C-VEGF and VEGFR2 were 22.2, 12.1 and 13.9, respectively.
- various dual-target fusion proteins can bind to more than two receptors, with the ability to dual target.
- RGD-EGF and RGD4C-EGF can bind to Integrin ( ⁇ v ⁇ 3) and EGFR, respectively, and RGD-VEGF and RGD4C-VEGF can bind to Integrin ( ⁇ v ⁇ 3), VEGFR1 and VEGFR2, respectively.
- This example uses MDA-MB468 (highly expressed EGFR), MDA-MB231 (moderately expressed EGFR), MCF-7 (low performance), HT1080 (expressed APN), U87MG (expressed ⁇ v ⁇ 3) and HUVEC (expressed VEGFR and ⁇ v ⁇ 3) Cell lines to analyze the specific binding of the dual-target fusion protein to different receptors.
- MDA-MB468, MDA-MB231, MCF-7, HT1080, U87MG and HUVEC cells were seeded in a 96-well microplate at a dose of 20,000 cells/well, and cultured at 37 ° C for 12 hours. After the cells were attached, they were fixed with 4% paraformaldehyde hyde precooled at 4 ° C, and then incubated at room temperature for 15 minutes. After the fixed cells were incubated with 3% FBS at 25 ° C for 1 hour, serially diluted target fusion proteins were added and incubated at 25 ° C for 1 hour.
- the mouse anti-His-HRP antibody was used to detect the binding of the protein to the cells, and then the TMP of the HRP was used for color measurement.
- the absorbance at a wavelength of 450 nm was used for quantify the amount of protein bound to the cells.
- VEGF, RGD-VEGF, RGD4C- VEGF, NGR-VEGF and VEGFR intergrin solution on HUVEC cells with a dissociation constant K d values of 12.7,11.9,6.4 and 9.4nM.
- RGD-EGF, RGD4C-EGF, RGD-VEGF, and RGD4C-VEGF can bind to cells expressing the corresponding receptor.
- This example uses an ECM cell adhesion analysis system to analyze the adhesion characteristics of cells.
- Different concentrations of the target fusion protein were coated per well in a 96-well microplate and incubated at 16 ° C for 12 hours. After the protein was attached, 3% BSA was added and incubated at 25 ° C for 1 hour.
- Tumor cells U87MG, 5 ⁇ 10 5 cells/well
- Tumor cells that had been starved for one hour were added to a 96-well microplate, and after incubation at 37 ° C for 2 hours, they were washed with D-PBS to remove cells not bound to the protein.
- MTT was added and incubated at 37 ° C for 1 hour.
- the surviving cells metabolized the MTT agent to formazan blue-violet crystals.
- the wax was dissolved in DMSO to detect the absorbance at a wavelength of 570 nm.
- the cell attachment characteristics were calculated by the following formula.
- FIGS 4A-D RGD-VEGF and RGD4C-VEGF were applied to the cell disk After that, the number of U87MG cells and HUVEC cells attached to the culture plate can be increased, and if a large amount of RGD peptide chain is added to compete, the adsorption of cells can be reduced.
- Figure 4A shows that RGD-VEGF and RGD4C-VEGF are coated on the cell plate to increase the amount of U87MG cells attached to the culture plate
- Figure 4B shows the amount of cells attached to the plate after the addition of the RGDfV polypeptide.
- Figure 4C-4D shows that RGD-VEGF and RGD4C-VEGF bind to HUVEC cells, and then compete with RGDfV polypeptide or VEGFR2 recombinant protein, respectively, in terms of absorbance and percentage.
- the fusion protein activates the cellular receptor and its downstream signaling molecule phosphorylation.
- Various human tumor cells were cultured with 25nM target fusion protein at 37 ° C for 60 minutes to collect intracellular protein extracts, and the phosphorylation reaction of cell receptors and their downstream signal molecules was analyzed by Western blotting method.
- RGD-EGF and RGD4C-EGF were co-cultured with MDA-MB468 cells expressing EGFR; or RGD-VEGF and RGD4C-VEGF were co-cultured with HUVEC vascular endothelial cells expressing VEGFR1 and VEGFR2.
- the signaling molecules downstream of EGFR (Fig. 5A) or VEGFR (Fig. 5B) were analyzed.
- RGD-EGF and RGD4C-EGF or RGD-VEGF and RGD4C-VEGF can activate the signaling pathway downstream of EGFR or VEGFR, respectively.
- the results show that the double target molecule of the present invention not only has the ability to bind to a relatively biomarker molecule, but a large peptide molecule such as EGF or VEGF retains its original biological properties.
- p-SCN-Bn-DTPA 2-(4-Iso thiocyanatobenzyl-diethylenetriaminepentaacetic acid, p-SCN-Bn-DTPA) is dissolved in HEPES buffer solution, and RGD-EGF is added.
- RGD4C-EGF was reacted at room temperature for 1 hour.
- the unreacted small molecule reactant was removed by colloidal chromatography (Sephadax G25) to obtain a radioactive marker precursor protein such as DTPA-RGD-EGF and DTPA-RGD4C-EGF.
- HEPES buffer solution An appropriate amount of HEPES buffer solution and radioactive ( 111 InCl 3 , 67 GaCl 3 , 90 YCl 3 and 177 LuCl 3 , etc.) were added to the above-mentioned fusion protein solution bound to DTPA, and reacted at room temperature for 1 hour. Excess EDTA was added to chelate the radioactive metal ions not bound to the protein, and purified by membrane filtration centrifugation and colloidal chromatography. The activity was measured and the radiochemical purity of the product was analyzed by radioactive thin layer analysis. The stability of the fusion protein in buffer solution (HEPES, 4 ° C) and serum (37 ° C).
- radioactive 111 InCl 3 , 67 GaCl 3 , 90 YCl 3 and 177 LuCl 3 , etc.
- Tumor cells or vascular cells were cultured in a 12-well cell culture dish at 37 ° C for one day in a CO 2 incubator.
- the medium in the culture plate was removed, and the cells were washed with 1 mL of PBS, and then VEGF, RGD-VEGF and RGD4C-VEGF were separately added, and the cells were allowed to stand at 37 ° C for 2 hours in a CO 2 incubator.
- Tumor mice (tumor size about 50-100 mm 3 ) were injected with 500 ⁇ Ci of radiolabeled recombinant protein in the tail vein, respectively.
- Small animal SPECT/CT angiography was performed at 1, 2, 4, 8, 24, 48 and 72 hours after the injection. After the end of the angiography, the image was processed by software, and the tumor to muscle ratio was calculated by ROI (region of interest) analysis to evaluate the dynamic accumulation of the drug in the living body of the animal.
- ROI region of interest
- Computed tomography angiography.
- the image shows that after the In-111 marker recombinant protein is applied, the specific accumulation of the tumor in the tumor (expressed as the tumor/muscle accumulation ratio) increases with time, reaching a peak at 8 hours after the drug injection, at this time 111 In
- the tumor/muscle accumulation ratio of -DTPA-RGD4C-EGF was 4.4, slightly higher than 3.6 of 111 In-DTPA-RGD-EGF, and much higher than 1.7 of 111 In-DTPA-EGF.
- RGD4C-EGF and RGD-EGF fusion proteins have dual targeting ability, and the accumulation of tumors is significantly higher than that of EGF recombinant protein with only single target ability;
- the sequence of RGD4C-EGF fusion protein has better binding ability to integrin ⁇ v ⁇ 3, which makes it accumulate in tumors slightly better than RGD-EGF fusion protein with linear RGD sequence.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un vecteur de médicament à double ciblage comprenant une première molécule de ciblage et une seconde molécule de ciblage. La molécule de ciblage comprend un peptide, un anticorps ou une protéine. La molécule de ciblage est capable de se lier à un récepteur spécifique, ou à une protéine ou une glycoprotéine spécifique. La molécule cible peut également être conjuguée à un matériau de radiothérapie pour former un conjugué.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680083086.6A CN108699164B (zh) | 2016-03-02 | 2016-03-02 | 双重标靶药物载体 |
PCT/CN2016/075329 WO2017147820A1 (fr) | 2016-03-02 | 2016-03-02 | Vecteur de médicament à double ciblage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2016/075329 WO2017147820A1 (fr) | 2016-03-02 | 2016-03-02 | Vecteur de médicament à double ciblage |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017147820A1 true WO2017147820A1 (fr) | 2017-09-08 |
Family
ID=59743389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/075329 WO2017147820A1 (fr) | 2016-03-02 | 2016-03-02 | Vecteur de médicament à double ciblage |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108699164B (fr) |
WO (1) | WO2017147820A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108187064A (zh) * | 2017-11-28 | 2018-06-22 | 南京大学 | 一种类弹性蛋白-抗EGFR纳米抗体-iRGD的双靶向融合蛋白阿霉素偶联体的制法和用途 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113307857B (zh) * | 2021-01-14 | 2022-11-01 | 艾时斌 | 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1766115A (zh) * | 2005-09-06 | 2006-05-03 | 中国人民解放军第四军医大学 | 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法 |
CN101124243A (zh) * | 2004-12-23 | 2008-02-13 | 莫尔梅德股份有限公司 | 缀合产物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372172B1 (en) * | 1997-12-19 | 2002-04-16 | Kimberly-Clark Worldwide, Inc. | Nonwoven webs having improved softness and barrier properties |
-
2016
- 2016-03-02 CN CN201680083086.6A patent/CN108699164B/zh active Active
- 2016-03-02 WO PCT/CN2016/075329 patent/WO2017147820A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101124243A (zh) * | 2004-12-23 | 2008-02-13 | 莫尔梅德股份有限公司 | 缀合产物 |
CN1766115A (zh) * | 2005-09-06 | 2006-05-03 | 中国人民解放军第四军医大学 | 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108187064A (zh) * | 2017-11-28 | 2018-06-22 | 南京大学 | 一种类弹性蛋白-抗EGFR纳米抗体-iRGD的双靶向融合蛋白阿霉素偶联体的制法和用途 |
CN108187064B (zh) * | 2017-11-28 | 2021-05-28 | 南京大学 | 一种类弹性蛋白-抗EGFR纳米抗体-iRGD的双靶向融合蛋白阿霉素偶联体的制法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN108699164A (zh) | 2018-10-23 |
CN108699164B (zh) | 2022-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7127008B2 (ja) | イメージングのための新規pd-l1結合ポリペプチド | |
KR102397783B1 (ko) | Pd-l1 결합 폴리펩티드에 의한 pet 영상화 | |
US8299030B2 (en) | Peptide-based compounds | |
JPWO2017217347A1 (ja) | IgG結合ペプチドによる部位特異的RI標識抗体 | |
CA2891190C (fr) | Conjugues polypeptide derive d'aprotinine-anticorps | |
US20160106858A1 (en) | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers | |
KR20200143366A (ko) | 수식 항체 및 방사성 금속 표지 항체 | |
WO2011071279A2 (fr) | Système de transfert de charge à base de liant peptidique bipode | |
KR101286721B1 (ko) | 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법 | |
TWI602577B (zh) | 雙重標靶融合蛋白 | |
Chastel et al. | Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides | |
WO2017147820A1 (fr) | Vecteur de médicament à double ciblage | |
JP6612063B2 (ja) | 悪性神経膠腫分子標的ペプチド | |
US11357863B2 (en) | Peptide conjugates | |
JP7512392B2 (ja) | 新規診断用分子プローブとしての抗her2ポリペプチド誘導体 | |
US20130323171A1 (en) | Radiolabeled bbn analogs for pet imaging of gastrin-releasing peptide receptors | |
JP7511647B2 (ja) | 新規診断用分子プローブとしての抗her2ポリペプチド誘導体 | |
WO2024046469A1 (fr) | Peptide cyclique et son procédé de préparation, et complexe le comprenant et son utilisation | |
US20230365636A1 (en) | Bioorthogonal reporter gene system | |
JP2024506070A (ja) | 新規her2結合ポリペプチド | |
CN117327183A (zh) | 核素标记Trop2特异性单域抗体探针制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16892011 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16892011 Country of ref document: EP Kind code of ref document: A1 |